Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
š¼
SK
or Search
SIGN UP
SIGN IN
ENTITY
Asymchem Laboratories Tianjin (002821 CH)
Watchlist
101
Analysis
Health Care
ā¢
China
Asymchem Laboratories (Tianjin) Co., Ltd. operates as a pharmaceutical company. The Company researches, produces, and sells organic and inorganic chemicals, medicines, and other related products. Asymchem Laboratories serves customers worldwide.
more
Watchlist
All
Insights
Primers
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
ā¢
Asymchem Laboratories Tianjin
ā¢
21 Nov 2021 08:29
Asymchem Labs A/H Listing - PHIP Updates and a Look at Valuations
Asymchem Laboratories (AL) aims to raise around US$1-1.5bn in its H-share listing in Hong Kong. In this note, we talk about recent updates, peer...
Sumeet Singh
Follow
520 Views
Share
bullish
ā¢
Cisarua Mountain Dairy
ā¢
14 Nov 2021 08:49
ECM Weekly (14th November 2021) - Cimory, Infervision, Daiwa House REIT, Weilong Delicious
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.
Sumeet Singh
Follow
535 Views
Share
bullish
ā¢
Shanghai MicroPort MedBot
ā¢
26 Sep 2021 11:33
ECM Weekly (26th September 2021) - Hanyu Med, Abbisko, SenseTime, ANE, Nykaa, Prudential HK
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.
Sumeet Singh
Follow
653 Views
Share
bullish
ā¢
WuXi AppTec
ā¢
21 Sep 2021 08:59
WuXi AppTec (603259.CH/2359.HK) - The Smart Business Model
The article mainly analyzed WuXi AppTec in terms of itsĀ 2021/1H performance,the business model(traditional CRO/CDMO services, venture and fund...
Xinyao (Criss) Wang
Follow
446 Views
Share
bearish
ā¢
Asymchem Laboratories Tianjin
ā¢
19 Aug 2021 08:53
Asymchem Laboratories (002821.CH) 2021H1 Results - Not Good Enough
This article analyzed Asymchem in terms of its 2021/1H financial results, the comparison with peers,Ā the concerns on growth, the valuation and the...
Xinyao (Criss) Wang
Follow
341 Views
Share
First
Previous
15
16
17
18
19
20
Next
Last
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
How Smartkarma Compares
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright Ā© 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.4
x